All In Biotech

Drug Trial Radar · NCT06024772

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Mp-US) - Targeted Biopsy; Targeted Biopsy Cores Based on Mp-US Compared With Targeted Biopsy Based on Mp-MRI, for Detection of Clinically Significant PCa.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Aug 1, 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Thomas Jefferson UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amsterdam UMC, location VUmc; Eindhoven University of Technology; Eigen; GE Healthcare; National Cancer Institute (NCI)
First posted
Sep 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether multiparametric ultrasound (mp-US) can detect clinically significant prostate cancer as effectively as multiparametric MRI (mp-MRI) in adult men undergoing prostate biopsy for suspected prostate cancer. The main questions it aims to answer are: Does mp-US-guided targeted biopsy detect clinically significant prostate cancer at a rate that is not inferior to mp-MRI-guided targeted biopsy? Can mp-US imaging collected at the time of biopsy be used to identify suspicious prostate lesions for targeted sampling? Researchers will compare mp-US-guided targeted biopsy plus systematic biopsy with mp-MRI-guided targeted biopsy plus systematic biopsy to see if mp-US achieves a similar detection rate for clinically significant prostate cancer. Participants will: Undergo mp-MRI within 30 days before prostate biopsy. Receive mp-US imaging at the time of biopsy. Undergo up to three mp-US-targeted biopsy cores of suspicious areas. Undergo up to three mp-MRI-targeted biopsy cores of suspicious areas. Receive a standard systematic prostate biopsy consisting of 12 biopsy cores.

Conditions

  • Prostate Carcinoma

Interventions

  • ultiparametric Magnetic Resonance ImagingProcedure

    Undergo mp-MRI

  • Perflutren lipid microsphereDrug

    Given IV

  • Transrectal UltrasoundProcedure

    Undergo transrectal mp-US

  • Biopsy of ProstateProcedure

    Undergo prostate biopsies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prostate cancer (PCa) detection rate of 3-dimensional (3D) multiparametric ultrasound (mp-US) combined with systematic biopsyTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.